1 |
Gulamhusein AF, Hirschfield GM. Hirschfield GM Primary biliary cholangitis: pathogenesis and therapeutic opportunities[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(2):93-110.
|
2 |
Shah RA, Kowdley KV. Current and potential treatments for primary biliary cholangitis[J]. Lancet Gastroenterol Hepatol, 2020, 5(3):306-315.
|
3 |
European Association for the Study of the Liver. EASL Clinical Practice Guidelines:management of cholestatic liver diseases[J]. J Hepatol, 2009, 51(2):237-267.
|
4 |
Harrell CR, Sadikot R, Pascual J, et al. Mesenchymal stem cell-based therapy of inflammatory lung diseases:current understanding and future perspectives[J]. Stem Cells Int, 2019, 2019:4236973.doi: 10.1155/2019/4236973.
|
5 |
Watanabe Y, Tsuchiya A, Terai S. The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future[J]. Clin Mol Hepatol, 2021, 27(1):70-80.
|
6 |
Sun L, Wang D, Liang J, et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus[J]. Arthritis Rheum, 2010, 62(8):2467-2475.
|
7 |
Liu Y, Mu R, Wang S, et al. Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis[J]. Arthritis Res Ther, 2010, 12(6):R210.doi: 10.1186/ar3187.
|
8 |
Ono-Uruga Y, Ikeda Y, Matsubara Y. Platelet production using adipose-derived mesenchymal stem cells:Mechanistic studies and clinical application[J]. J Thromb Haemost, 2021, 19(2):342-350.
|
9 |
Yun CW, Lee SH. Potential and therapeutic efficacy of cell-based therapy using mesenchymal stem cells for acute/chronic kidney disease[J]. Int J Mol Sci, 2019, 20(7):1619. doi: 10.3390/ijms20071619.
|
10 |
Meng F, Xu R, Wang S, et al. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19:a phase 1 clinical trial[J]. Signal Transduct Target Ther, 2020, 5(1):172.
|
11 |
Yang X, Meng Y, Han Z, et al. Mesenchymal stem cell therapy for liver disease:full of chances and challenges[J]. Cell Biosci, 2020, 10:123.
|
12 |
Peng L, Xie DY, Lin BL, et al. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B:short-term and long-term outcomes[J]. Hepatology, 2011, 54(3):820-828.
|
13 |
Amer ME, El-Sayed SZ, El-Kheir WA, et al. Clinical and laboratory evaluation of patients with end-stage liver cell failure injected with bone marrow-derived hepatocyte-like cells[J]. Eur J Gastroenterol Hepatol, 2011, 23(10):936-941.
|
14 |
Suk KT, Yoon JH, Kim MY, et al. Transplantation with autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis:phase 2 trial[J]. Hepatology, 2016, 64(6):2185-2197.
|
15 |
Shi M, Liu Z, Wang Y, et al. A pilot study of mesenchymal stem cell therapy for acute liver allograft rejection[J]. Stem Cells Transl Med, 2017, 6(12):2053-2061.
|
16 |
Liang J, Zhang H, Zhao C, et al. Effects of allogeneic mesenchymal stem cell transplantation in the treatment of liver cirrhosis caused by autoimmune diseases[J]. Int J Rheum Dis, 2017, 20(9):1219-1226.
|
17 |
Wang L, Li J, Liu H, et al. Pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis[J]. J Gastroenterol Hepatol, 2013, Suppl 1:85-92.
|
18 |
Wang L, Han Q, Chen H, et al. Allogeneic bone marrow mesenchymal stem cell transplantation in patients with UDCA-resistant primary biliary cirrhosis[J]. Stem Cells Dev, 2014, 23(20):2482-2489.
|
19 |
Lindor KD, Bowlus CL, Boyer J, et al. primary biliary cholangitis:2018 practice guidance from the American Association for the study of liver diseases[J]. Hepatology, 2019, 69(1):394-419.
|
20 |
Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis[J]. Hepatology, 2008, 48(3):871-877.
|
21 |
徐小元,丁惠国,李文刚等.肝硬化诊治指南[J].临床肝胆病杂志,2019,35(11):2408-2425.
|
22 |
Li S, Bi Y, Duan Z, et al. Stem cell transplantation for treating liver diseases:progress and remaining challenges[J]. Am J Transl Res, 2021, 13(5):3954-3966.
|
23 |
Liu WH, Song FQ, Ren LN, et al. The multiple functional roles of mesenchymal stem cells in participating in treating liver diseases[J]. J Cell Mol Med, 2015, 19(3):511-520.
|
24 |
Wang D, Zhang H, Liang J, et al. Effect of allogeneic bone marrow-derived mesenchymal stem cells transplantation in a polyI:C-induced primary biliary cirrhosis mouse model[J]. Clin Exp Med, 2011, 11(1):25-32.
|
25 |
Fisk JD, Ritvo PG, Ross L, et al. Measuring the functional impact of fatigue:initial validation of the fatigue impact scale[J]. Clin Infect Dis, 1994, Suppl 1:S79-83.
|
26 |
Elman S, Hynan LS, Gabriel V, et al. The 5-D itch scale:a new measure of pruritus[J]. Br J Dermatol, 2010, 162(3):587-593.
|
27 |
Brückner S, Zipprich A, Hempel M, et al. Improvement of portal venous pressure in cirrhotic rat livers by systemic treatment with adipose tissue-derived mesenchymal stromal cells[J]. Cytotherapy, 2017, 19(12):1462-1473.
|
28 |
Pietrosi G, Fernández-Iglesias A, Pampalone M, et al. Human amniotic stem cells improve hepatic microvascular dysfunction and portal hypertension in cirrhotic rats[J]. Liver Int, 2020, 40(10):2500-2514.
|
29 |
Wan YM, Li ZQ, Liu C, et al. Mesenchymal stem cells reduce alcoholic hepatitis in mice via suppression of hepatic neutrophil and macrophage infiltration, and of oxidative stress[J]. PloS one, 2020, 15(2):e0228889.doi: 10.1371/journal.pone.0228889.
|